Alimera Sciences (NASDAQ:ALIM) Coverage Initiated at started coverage on shares of Alimera Sciences (NASDAQ:ALIMGet Rating) in a research note issued to investors on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on ALIM. Zacks Investment Research upgraded Alimera Sciences from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 27th. HC Wainwright decreased their price objective on Alimera Sciences from $10.00 to $8.00 in a research report on Tuesday. Finally, Alliance Global Partners reduced their price target on Alimera Sciences from $14.50 to $11.00 in a research report on Friday, February 25th.

Shares of ALIM opened at $4.00 on Friday. The stock has a 50 day simple moving average of $5.53 and a 200 day simple moving average of $5.10. Alimera Sciences has a 52-week low of $3.94 and a 52-week high of $10.50. The firm has a market capitalization of $27.97 million, a PE ratio of -5.06 and a beta of 1.48.

Alimera Sciences (NASDAQ:ALIMGet Rating) last issued its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.16). During the same quarter last year, the business posted ($0.63) earnings per share. As a group, research analysts anticipate that Alimera Sciences will post -1.89 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in ALIM. Millennium Management LLC acquired a new position in Alimera Sciences during the 4th quarter worth approximately $65,000. Ensign Peak Advisors Inc acquired a new position in Alimera Sciences during the 3rd quarter worth approximately $81,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Alimera Sciences during the 1st quarter worth approximately $1,400,000. Finally, Morgan Stanley raised its stake in shares of Alimera Sciences by 0.7% during the 2nd quarter. Morgan Stanley now owns 428,109 shares of the biopharmaceutical company’s stock worth $3,896,000 after purchasing an additional 2,797 shares in the last quarter. 40.97% of the stock is owned by hedge funds and other institutional investors.

Alimera Sciences Company Profile (Get Rating)

Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

See Also

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.